Terms: = Germ cell tumor AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Treatment
38 results:
1. SPI1-mediated MIR222HG transcription promotes proneural-to-mesenchymal transition of glioma stem cells and immunosuppressive polarization of macrophages.
Fan Y; Gao Z; Xu J; Wang H; Guo Q; Li B; Li M; Xu H; Qi Y; Zhao S; Qiu W; Pan Z; Wang Q; Xue H; Zhao R; Guo X; Li G
Theranostics; 2023; 13(10):3310-3329. PubMed ID: 37351164
[No Abstract] [Full Text] [Related]
2. Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.
Gordon S; Chan DLH; Bernard EJ; Eslick ME; Willowson KP; Roach PJ; Engel AF; Maher R; Clarke SJ; Agarwal V; Yasmin L; De Silva M; Mascall S; Conner A; Nevell D; Pavlakis N; Bailey DL
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7717-7728. PubMed ID: 37004598
[TBL] [Abstract] [Full Text] [Related]
3. Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Farheen S; Ahmed SP; Mariyath P M M; Kausar T; Hoda MF; Arif SH; Nayeem SM; Ali A; Chosdol K; Shahi MH
J Biochem Mol Toxicol; 2023 Feb; 37(2):e23241. PubMed ID: 36205257
[TBL] [Abstract] [Full Text] [Related]
4. Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms.
Park R; Amin M; Trikalinos NA
J Neuroendocrinol; 2022 Jul; 34(7):e13178. PubMed ID: 35854663
[TBL] [Abstract] [Full Text] [Related]
5. Long-term survival and toxicity in patients with neuroendocrine tumors treated with
Kennedy KR; Turner JH; MacDonald WBG; Claringbold PG; Boardman G; Ransom DT
Cancer; 2022 Jun; 128(11):2182-2192. PubMed ID: 35363879
[TBL] [Abstract] [Full Text] [Related]
6. Immunodepletion of mdsC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in mds and melanoma.
Cheng P; Chen X; Dalton R; Calescibetta A; So T; Gilvary D; Ward G; Smith V; Eckard S; Fox JA; Guenot J; Markowitz J; Cleveland JL; Wright KL; List AF; Wei S; Eksioglu EA
Mol Ther; 2022 Jun; 30(6):2315-2326. PubMed ID: 35150889
[TBL] [Abstract] [Full Text] [Related]
7. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
Morra A; Escala-Garcia M; Beesley J; Keeman R; Canisius S; Ahearn TU; Andrulis IL; Anton-Culver H; Arndt V; Auer PL; Augustinsson A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brenner H; Brüning T; Buys SS; Caan B; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Cheng TD; Clarke CL; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Dörk T; Dossus L; Dunning AM; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; Gago-Dominguez M; García-Sáenz JA; Giles GG; Grip M; Guénel P; Gündert M; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Hart SN; Hartikainen JM; Hartmann A; He W; Hooning MJ; Hoppe R; Hopper JL; Howell A; Hunter DJ; ; ; Jager A; Jakubowska A; Janni W; John EM; Jung AY; Kaaks R; Keupers M; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kurian AW; Lacey JV; Lambrechts D; Le Marchand L; Lindblom A; Linet M; Luben RN; Lubiński J; Lush M; Mannermaa A; Manoochehri M; Margolin S; Martens JWM; Martinez ME; Mavroudis D; Michailidou K; Milne RL; Mulligan AM; Muranen TA; Nevanlinna H; Newman WG; Nielsen SF; Nordestgaard BG; Olshan AF; Olsson H; Orr N; Park-Simon TW; Patel AV; Peissel B; Peterlongo P; Plaseska-Karanfilska D; Prajzendanc K; Prentice R; Presneau N; Rack B; Rennert G; Rennert HS; Rhenius V; Romero A; Roylance R; Ruebner M; Saloustros E; Sawyer EJ; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Smichkoska S; Southey MC; Stone J; Surowy H; Swerdlow AJ; Tamimi RM; Tapper WJ; Teras LR; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Truong T; Vachon CM; Wang Q; Hurson AN; Winqvist R; Wolk A; Ziogas A; Brauch H; García-Closas M; Pharoah PDP; Easton DF; Chenevix-Trench G; Schmidt MK
Breast Cancer Res; 2021 Aug; 23(1):86. PubMed ID: 34407845
[TBL] [Abstract] [Full Text] [Related]
8. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111
[TBL] [Abstract] [Full Text] [Related]
9. (Carboxymethyl-stevioside)-coated magnetic dots for enhanced magnetic hyperthermia and improved glioblastoma treatment.
Gupta R; Sharma D
Colloids Surf B Biointerfaces; 2021 Sep; 205():111870. PubMed ID: 34034224
[TBL] [Abstract] [Full Text] [Related]
10. Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma.
Park JE; Kim HS; Kim N; Kim YH; Kim JH; Kim E; Hwang J; Katscher U
Eur Radiol; 2021 Sep; 31(9):6655-6665. PubMed ID: 33880619
[TBL] [Abstract] [Full Text] [Related]
11. A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Cai Y; Jiang YG; Wang M; Jiang ZH; Tan ZG
Medicine (Baltimore); 2020 Sep; 99(38):e22238. PubMed ID: 32957367
[TBL] [Abstract] [Full Text] [Related]
12. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine tumors and Research Opportunities.
Shaheen S; Moradi F; Gamino G; Kunz PL
Curr Treat Options Oncol; 2020 Mar; 21(4):25. PubMed ID: 32172368
[TBL] [Abstract] [Full Text] [Related]
13. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
[TBL] [Abstract] [Full Text] [Related]
14. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
[TBL] [Abstract] [Full Text] [Related]
15. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract] [Full Text] [Related]
16. The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis.
Lu VM; Texakalidis P; McDonald KL; Mekary RA; Smith TR
Clin Neurol Neurosurg; 2018 Nov; 174():149-155. PubMed ID: 30243186
[TBL] [Abstract] [Full Text] [Related]
17. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract] [Full Text] [Related]
18. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists.
Cockerell CJ; Tschen J; Evans B; Bess E; Kidd J; Kolquist KA; Rock C; Clarke LE
Medicine (Baltimore); 2016 Oct; 95(40):e4887. PubMed ID: 27749545
[TBL] [Abstract] [Full Text] [Related]
19. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract] [Full Text] [Related]
20. Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.
Greenplate AR; Johnson DB; Roussel M; Savona MR; Sosman JA; Puzanov I; Ferrell PB; Irish JM
Cancer Immunol Res; 2016 Jun; 4(6):474-480. PubMed ID: 26966176
[TBL] [Abstract] [Full Text] [Related]
[Next]
